自从近30年前首次引入全细胞生物报道分子(WCB)以来,他们的高灵敏度,选择性,和现场检测的适用性使它们在环境监测中具有很大的前景,医学诊断,食品安全,生物制造,和其他领域。特别是在环境领域,该技术提供了一种快速有效的方法来评估环境中污染物的生物利用度。尽管有这些优势,该技术尚未商业化。这种商业化的缺乏令人困惑,鉴于WCBs广阔的应用前景。多年来,许多研究论文主要集中在增强WCB的灵敏度和选择性上,很少关注它们更广泛的商业应用。到目前为止,目前还没有关于这个主题的批判性审查。因此,在本文中,我们批判性地回顾了WCB在过去三十年中的研究进展,评估当前系统的性能和局限性,以了解商业部署的障碍。通过识别这些障碍,本文为研究人员和行业利益相关者提供了对阻碍市场进入的挑战的更深入的见解,并激发了克服这些障碍的进一步研究,从而促进WCB的商业化,作为一种有前途的环境监测技术。
Since the initial introduction of whole-cell bioreporters (WCBs) nearly 30 years ago, their high sensitivity, selectivity, and suitability for on-site detection have rendered them highly promising for environmental monitoring, medical diagnosis, food safety, biomanufacturing, and other fields. Especially in the environmental field, the technology provides a fast and efficient way to assess the bioavailability of pollutants in the environment. Despite these advantages, the technology has not been commercialized. This lack of
commercialization is confusing, given the broad application prospects of WCBs. Over the years, numerous research papers have focused primarily on enhancing the sensitivity and selectivity of WCBs, with little attention paid to their wider commercial applications. So far, there is no a critical review has been published yet on this topic. Therefore, in this article we critically reviewed the research progress of WCBs over the past three decades, assessing the performance and limitations of current systems to understand the barriers to commercial deployment. By identifying these obstacles, this article provided researchers and industry stakeholders with deeper insights into the challenges hindering market entry and inspire further research toward overcoming these barriers, thereby facilitating the
commercialization of WCBs as a promising technology for environmental monitoring.